Finding the Medications No One Else Can

Parth came to the US in 2019 to pursue his master’s degree. After graduating, he started his first company in the US. Medfinder is his second startup, built around a problem that is both deeply practical and surprisingly painful: patients often cannot find the medications they need, even after a doctor has prescribed them. Rather than starting with a broad healthcare platform, Parth focused on a very specific bottleneck in the patient journey: medication availability. In the US, delivery is not always the hardest part. The bigger issue is often knowing which pharmacy actually has the medication in stock.

Medfinder helps patients find hard-to-find medications that may be in shortage, backordered, or unavailable at nearby pharmacies. Patients are often told to “call around,” which can mean spending hours contacting pharmacy after pharmacy with no clear answer. Medfinder replaces that manual search process. Medfinder’s website describes the problem simply: “Stop calling pharmacy after pharmacy,” and says users can tell Medfinder what they need so the company can find it in stock nearby.

Medfinder uses AI voice agents to call pharmacies, speak with pharmacists, and gather real-time stock information. In Parth’s words, the voice agents call pharmacies, talk to the pharmacist, and collect availability data so patients can find where their medication is actually in stock. This is especially useful for medications where public availability data is limited or unreliable. Parth noted that shortage lists can underrepresent what patients are actually experiencing on the ground. Medfinder focuses on the practical reality: the medication only helps if a pharmacy can actually fill it.

Medication shortages affect a wide range of patients. Parth pointed to examples like controlled substances, specialized cancer drugs, and high-demand GLP-1 medications as categories where availability can become difficult. Medfinder’s website similarly highlights stimulant shortages, GLP-1 backorders, specialty drugs, rare disease treatments, limited-distribution drugs, and other medications affected by shortage or limited supply.

Medfinder is already generating revenue and has an annual run rate. Parth also shared that the company raised a pre-seed round, and he believes Medfinder has significantly stronger market penetration than competitors in this still-new category.

Parth describes the current challenge as execution: making the team more efficient, increasing revenue, and improving support services. Rather than framing the company’s next phase around a single massive hurdle, he sees the work ahead as disciplined operational improvement. For Medfinder, the vision is straightforward but high-impact: make it dramatically easier for patients to access medications that already exist but are difficult to find. By combining AI-driven pharmacy outreach with human support, Medfinder is building infrastructure for one of healthcare’s most frustrating last-mile problems.